March 23, 2026 01:41 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Mamata unveils TMC candidate list for Bengal polls; to face Suvendu in Bhabanipur | ‘Not a one-day battle for me’: Mamata Banerjee on facing Suvendu Adhikari in Bhabanipur | Mamata vs Suvendu: Bhabanipur set for high-voltage showdown | Barbaric: India condemns Pakistani airstrike on Kabul hospital | Middle East conflict: Israel says it killed key Iranian commander during overnight strike | Middle East on edge: Kataeb Hezbollah commander Abu Ali al-Askari killed | Middle East on edge: Kataeb Hezbollah commander Abu Ali al-Askari killed | Afghanistan claims Pakistani airstrike on Kabul hospital left 400 killed, Islamabad denies | ECI orders major reshuffle in Bengal police brass a day after poll announcement | 10 patients killed in fire at SCB Medical College Hospital in Cuttack; staff injured

Singapore to begin human clinical trials on potential coronavirus treatment - Reports

| @indiablooms | Jun 10, 2020, at 04:26 pm

Moscow/Sputnik/UNI: Singapore will begin human clinical trials on a domestically developed treatment candidate for the coronavirus next week, media reported Wednesday.

According to the Singapore news outlet, The Strait Times, biotechnology company Tychan will administer the experimental treatment to 23 healthy individuals and monitor the results over six weeks.

The medication in question is the TY027, which was developed to specifically target Sars-Cov-2, the virus that causes COVID-19, the newspaper reported.

The medication is being studied for qualities of slowing the spread of the virus, speeding up recovery and even protecting against the infection, according to The Strait Times.

Tychan is one of the dozens of companies around the world racing to develop treatments and vaccines against the coronavirus, which has so far infected more than 7.3 million people and killed over 410,000. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.